MedDataX Logo

Serial Comparisons of Abdominal and Neurological MRI Scans

NCT ID: NCT02009969

Last Updated: 2015-12-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-09-30

Study Completion Date

2017-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare abdominal weight gain and fat distribution to changes in brain morphology in people taking antipsychotic medications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Abdominal weight gain is a significant side effect of antipsychotic medications. It has even been suggested to be part of the pathology of severe mental illnesses. Studies have shown that in persons with bipolar disorder, increased body mass index (BMI) is associated with irregular changes in the brain. This association has not been tested in persons with psychosis. In this study, we will be measuring abdominal fat distribution as measured by MRI to see if this is associated with abnormal brain morphology.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psychotic Disorders

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Psychosis Adverse effects Symptom Severity Magnetic Resonance Imaging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be admitted to the BC (British Columbia) Psychosis Program at UBC (University of British Columbia) Hospital
* Must have clinically diagnosed psychosis (e.g. schizophrenia)
* Must be fluent in English
* Must not be contraindicated for MRI (i.e., must not be claustrophobic, have metal in the body, be pregnant, have BMI greater than or equal to 40, etc.)

Exclusion Criteria

• None, other than those listed above
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of British Columbia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alasdair M Barr, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

The University of British Columbia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

BC Mental Health & Addictions Research Institute

Vancouver, British Columbia, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Heidi N Boyda, Ph.D.

Role: CONTACT

Phone: 604-875-2000

Email: [email protected]

Delrae Fawcett, M.Sc.

Role: CONTACT

Phone: 604-875-2000

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Heidi N Boyda, Ph.D.

Role: primary

Delrae Fawcett, M.Sc.

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H13-01685

Identifier Type: -

Identifier Source: org_study_id